Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 2,351-2,375 of 3,186
CompletedNCT05165654

Improving Hallucinations by Targeting the rSTS With tES

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
Beth Israel Deaconess Medical Center
Condition
Schizophrenia
CompletedNCT04820309

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
CompletedNCT03681145

Youth to Text or Telehealth for Engagement in HIV Care

This study exists to see whether acceptance and commitment therapy, a talking treatment, is workable and worth testing more broadly. Researchers are trying to understand whether acceptance and commitment therapy, a talking treatment, can work better when mental health difficulties overlap with substance use.

DepressionOtherFrom 18 Years to 29 Years
Countries
United States
Sponsor
University of California, San Francisco
Condition
Depression
CompletedNCT03314129

Remediation of Visual Perceptual Impairments in People With Schizophrenia

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Rochester
Condition
Schizophrenia
TerminatedNCT03121586

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

This study exists to understand how the medication Pimavanserin holds up over time after the earliest research stage. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherOver 18 Years
Countries
Argentina, Bulgaria, Canada, Croatia, Czech Republic, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Ukraine, United States
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
CompletedNCT04325386

Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 22 Years to 85 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT01490086

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

This study exists to understand whether this type of care is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
India, Malaysia, Moldova, Philippines, United States
Sponsor
Reviva Pharmaceuticals
Condition
Schizophrenia
CompletedNCT05686239

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

This study exists to compare options and see whether the medication RL-007 offers something meaningfully different. Researchers are trying to understand whether the medication RL-007 can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Bulgaria, Czech Republic, Poland, United States
Sponsor
Recognify Life Sciences
Condition
Schizophrenia
CompletedNCT05905601

mHealth for Psychosis Help-seeking

This study exists to see whether psychoeducation, a guided learning and support program, is workable and worth testing more broadly. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 30 Years
Countries
United States
Sponsor
University of Washington
Condition
Schizophrenia
CompletedNCT03814967

Effects of Brain Stimulation on Higher-Order Cognition

This study exists to compare options and see whether brain scans or other body measurements offers something meaningfully different. Researchers are trying to understand whether brain scans or other body measurements can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
University of California, Davis
Condition
Schizophrenia
CompletedNCT03708315

BXCL501 for Agitation in Schizophrenia

This study exists to better understand the safety of a medication treatment and how manageable it feels in practice. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT05438160

Exploratory Study of a Digital Therapeutics in People With Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
Click Therapeutics, Inc.
Condition
Schizophrenia
CompletedNCT03034356

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
TerminatedNCT05182476

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
Bulgaria, Czech Republic, Serbia, Spain, United States
Sponsor
Neurocrine Biosciences
Condition
Schizophrenia
CompletedNCT00306475

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Northwestern University
Condition
Schizophrenia
CompletedNCT02237235

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

This study exists to compare options and see whether the medication MMFS-202 offers something meaningfully different. Researchers are trying to understand whether the medication MMFS-202 can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Northwestern University
Condition
Schizophrenia
CompletedNCT05537428

Song-making In a Group (SING) R61

This study exists to explore whether acceptance and commitment therapy, a talking treatment, could improve care and understanding. Researchers are trying to understand whether acceptance and commitment therapy, a talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT03183609

Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)

This study exists to compare options and see whether blood tests and biological markers offers something meaningfully different. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT05109065

Peripheral Immune System in Individuals With Schizophrenia

This study exists to learn from real-world information that can show how blood tests and biological markers fits into care. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United States
Sponsor
Stanford University
Condition
Schizophrenia